Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
P/E ratio for Sera Prognostics, Inc. (SERA)
P/E ratio as of 2023: -5.15
According to Sera Prognostics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.15. At the end of 2022 the company had a P/E ratio of -0.88.
P/E ratio history for Sera Prognostics, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.15 |
| 2022 | -0.88 |
| 2021 | -5.84 |
| 2020 | -16.91 |
| 2019 | -17.87 |